Anterior chamber IOLs lasts longer

Article

Anterior chamber intraocular lenses (IOLs) last twice as long as posterior chamber IOLs, before they need to be replaced.

Anterior chamber intraocular lenses (IOLs) last twice as long as posterior chamber IOLs, before they need to be replaced, according to a study published in the February issue of the Journal of Cataract and Refractive Surgery.

Frederico F. Marques and colleagues from the Complexe Hospitalar Padre Bento de Guarulhos, Brazil, reviewed the outcomes of 49 subjects who had undergone IOL exchange between 1986 and 2002. Fifteen patients had been implanted with an anterior chamber IOL and 34 with a posterior chamber IOL.

The mean interval between first surgery and lens exchange was 83.2 months in the anterior chamber group and 37.9 months in the posterior chamber group. The main reason for exchange in the anterior chamber group was inflammation resulting from uveitis-glaucoma-hyphaema syndrome or persistent iritis. In contrast, posterior chamber IOLs were more likely to become decentred or dislocated.

Best corrected visual acuity (BCVA) in the anterior chamber group, after exchange, improved in nine eyes (60%), was stable in four (27%) and worsened in two (13%). In the posterior chamber group, BCVA imporved in 17 eyes (50%), was stable in 11 (32%) and worsened in six (18%).

The researchers concluded that anterior chamber IOLs are able to last twice as long as posterior chamber IOLs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.